AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05363930 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel motorized spiral enteroscopy
Description: Novel motorized spiral enteroscopy (Olympus Medical Systems Corporation, Tokyo, Japan) procedures would be performed under general anaesthesia with nasotracheal intubation under fluoroscopic guidance. Four litres of PEG was given to all patients with at least 8 hours of fasting prior to NMSE. Initially antegrade enteroscopy would be performed failing which retrograde enteroscopy would be done to reach the lesion. If the desired lesion is not reached via antegrade/retrograde route, hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anesthesia using the same overtube. The time of procedure will be calculated from insertion of NMSE to its withdrawal. The depth of insertion would be measured by sequential withdrawal technique.
Study NCT05050630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR2-ICE
Description: Rituximab 375 mg/m2 d0; Lenalidomide 25mg/d d1-10; Ifosfamide 5g/m2 d2; Carboplatin calculate according to AUC=5 (single dose ≤800 mg); Etoposide 100mg/m2 d1-3; Tirelizumab 200mg d6.
Study NCT05363930 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single balloon enteroscopy
Description: Single balloon enteroscopy will be performed with single balloon video-enteroscope (Olympus Medical Systems, Tokyo, Japan) under monitored anaesthesia (deep sedation with propofol). Initially antegrade/retrograde enteroscopy would be performed based on pre-procedure localization failing which enteroscopy would be done from opposite route to reach the lesion. Hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anaesthesia using the same overtube. Duration of procedure would be calculated from the time of introduction of the enteroscope to time of removal. The depth of insertion would be measured using the push and pull technique.
Study NCT05110183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Description: A cochlear implant electrode will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software on a laptop computer will be used to control the delivery of a sequence of charge balanced current pules.
Study NCT05110183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: optical stimulation
Description: Optical fibers will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software will be used to control the delivery of a sequence of charge balanced current pules.
Study NCT05110183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined optical and electrical stimulation
Description: A short hybrid array consisting of optical sources and electrical contacts will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Biphasic electrical current pulse and optical pulse delivery will be controlled in amplitude and timing by a computer.
Study NCT05522335 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BBV154(Intranasal) & covaxin
Description: Intervention Covaxin
Study NCT04627701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omega
Description: Omega Implantation
Study NCT05059587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01
Description: MBA-P01 will be injected into the Glabellar line.
Study NCT05059587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX
Description: Botox will be injected into the Glabellar line.
Study NCT05914922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Tool
Description: 20 MSK short case simulations were developed based on authentic patient experiences. Strategies to optimize learning of MSK conditions to prepare learners for real-world clinical encounters would be important for family medicine resident learners. To address this need, 20 case simulations of 15 minute duration were developed. This study will determine if an online educational tool may be impactful for determining competency of family medicine resident learners in developing skills and knowledge of 20 MSK conditions while also determining if the tool impacts patient care and satisfaction.
Study NCT04986644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)
Description: Daily disposable contact lens wear for 1 week
Study NCT04986644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)
Description: Daily disposable contact lens wear for 1 week
Study NCT05474664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat mesylate
Description: 1. 4\~12 years old: Camostate mesylate 100 mg, 2 times a day~2. greater than 13 years old: Camostate mesylate 100 mg, 3 times a day
Study NCT05610410 — intervention group
Intervention type: OTHER
Intervention: Laser speckle contrast analysis
Description: Peripheral endothelial function assessment using Laser speckle contrast analysis and Peripheral reactive hyperemia assessment using EndoPAT
Study NCT05819827 — intervention group
Intervention type: OTHER
Intervention: Blood and Tissue
Description: Patients will collect stool for microbiome analysis at baseline (i.e., 3 +2 days prior to chemotherapy) and again 5-7 days following initiation of chemotherapy.~Blood samples will be collected prior to their first chemotherapy treatment, and in the second week after chemotherapy.
Study NCT06403644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovoTHOR XL Photobiomodulation Full Body Light Bed
Description: Low powered full-body photobiomodulation light bed therapy will be administered via the NovoTHOR XL light therapy bed which emits an average irradiance of \~30 mW/cm\^2.
Study NCT06403644 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NovoTHOR XL Photobiomodulation Full Body Light Bed
Description: Low powered full-body photobiomodulation light bed therapy will be administered via the NovoTHOR XL light therapy bed which emits an average irradiance of \~30 mW/cm\^2.
Study NCT06403644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ARRC LED Photobiomodulation Full Body Light Bed
Description: High powered full-body photobiomodulation light bed therapy will be administered via the ARRC LED light therapy bed which emits an average irradiance of \~75 mW/cm\^2.
Study NCT06403644 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ARRC LED Photobiomodulation Full Body Light Bed
Description: High powered full-body photobiomodulation light bed therapy will be administered via the ARRC LED light therapy bed which emits an average irradiance of \~75 mW/cm\^2.
Study NCT04925050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VB0004
Description: Each study part (A,B and C) will be completed sequentially or with partial overlapping. Safety and PK data through at least day 8 from a subsequent cohort will be reviewed by the SMC prior to dosing the fed period of FE cohort. Safety data will be assessed by SMC after completing each cohorts in MAD healthy volunteers and MAD mild Hypertension patients.
Study NCT04925050 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for VB0004
Description: Matching Placebo
Study NCT05245656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RB/RBAC alternating
Description: Patients assigned to the RB alternating with RBAC arm will receive six cycles of alternating RB (odd cycles) or RBAC (even cycles)~RB (1st, 3rd, and 5th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2~RBAC (2nd, 4th, and 6th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 70mg/m2, IV, D2-3~* Cytarabine 500mg/m2, IV, D2-4
Study NCT05245656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RB
Description: Every 4 weeks for 6 cycles~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2
Study NCT05004610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Lactate Solution
Description: continuous intravenous infusion of molar sodium lactate
Study NCT05310084 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection
Study NCT05310084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline intramuscular injection
Study NCT05464173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 10-30mg biw
Study NCT05464173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150mg or 100mg bid
Study NCT05464173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endocrinotherapy（doctor's choice）
Description: According to the drug insert
Study NCT05298774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-tech WPS
Description: G-tech WPS patches applied and activated within 4 hours of surgery
Study NCT06142903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7 versus 21 medically tailored meals per week
Description: Meals designed to support overall cardiovascular health will be provided to patients in their own home setting.
Study NCT06142903 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 7 versus 21 medically tailored meals per week
Description: Meals designed to support overall cardiovascular health will be provided to patients in their own home setting.
Study NCT05310084 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Inactivated Influenza Vaccine
Description: SIIV intramuscular injection
Study NCT05787782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo INVSENSOR00063
Description: Masimo INVSENSOR00063 will be used to measure temperature
Study NCT05499416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Self-administration of two (2-160 mg/mL \[1 mL\]) pre-filled syringes or autoinjectors at baseline (Day1) and at Weeks 4, 8,12, and 16
Study NCT05740696 — intervention group
Intervention type: PROCEDURE
Intervention: ALF
Description: Acute onset, no history of underlying liver disease, liver failure characterized by degree Ⅱ or above hepatic encephalopathy developed within 2 weeks
Study NCT05740696 — intervention group
Intervention type: PROCEDURE
Intervention: SALF
Description: The onset was acute, with no history of underlying liver disease, and clinical manifestations of liver failure appeared between 2 and 26 weeks
Study NCT05740696 — intervention group
Intervention type: PROCEDURE
Intervention: ACLF
Description: On the basis of chronic liver disease, the clinical manifestations of acute liver decompensation and liver failure appear in a short period
Study NCT05395208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic touch group accompanied by white noise
Description: During the intravenous catheter intervention, approximately 15-20 minutes of white noise was applied with therapeutic touch.
Study NCT06226025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Participants randomized to this intervention will take 1 oral pill (0.5 milligrams (mg)) daily. They will attend 4 weekly behavioral sleep intervention sessions with a therapist. In addition, participants will complete questionnaires (MyDataHelp app), monitor sleep, collect saliva samples, and wear the Fitbit Device.
Study NCT06226025 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to this intervention will take 1 oral placebo pill daily. They will attend 4 weekly behavioral sleep control sessions with a therapist. In addition, participants will complete questionnaires (MyDataHelp app), monitor sleep, collect saliva samples, and wear the Fitbit Device.
Study NCT06226025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral sleep intervention
Description: An active intervention that is typically paired with melatonin to maximize treatment effects.
Study NCT06226025 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral sleep control
Description: A behavioral placebo (which does not improve sleep in delayed sleep-wake phase disorder) to control for social/interpersonal effects of behavioral sleep intervention sessions.
Study NCT05525676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Relationship Checkup (BRC)
Description: The investigators are using the three 30-minute session protocol developed for Air Force Primary Care (Cigrang et al., 2016). Although it is simply referred to as the Marriage Checkup in that manuscript, the investigators use the name BRC to distinguish it from many other versions of Dr. James Cordova's Marriage Checkup (Cordova, 2014) adapted for different settings. Sessions in this version are briefer than other versions (30 mins vs. 60-90 mins) and this trial does not have any eligibility restrictions based on marital status.
Study NCT05322161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga classes
Description: There will be 6 total yoga classes (one introduced per week for a 6 week period). Each yoga session will be divided into three components, which will vary in duration based on a curriculum designed specifically with the post-partum state of mothers in mind:~1. Yoga postures (Asana) = low impact gentle postures meant to be done individually~2. Breathing techniques (Pranayama) = deliberate modifications of breath such as rapid diaphragmatic breathing, slow/deep breathing, alternate nostril breathing, breath holding~3. Meditation (Dhyana) = guided meditation
Study NCT05525676 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Co-Located Collaborative Care (CCC)
Description: The investigators are using the Co-Located Collaborative Care model developed by the VA Center for Integrated Healthcare to deliver at all VAs. Although the CCC model is flexible and can range from 1-6 sessions, in this study the investigators standardize the model to three sessions for a clear comparison with BRC. Session 1 uses the CCC Functional Assessment/Initial Assessment protocol. Sessions 2 \& 3 use the CCC Follow-up protocol.~Session 1 (25-30 min)- Veteran completes a functional assessment of concerns (15 mins) and then develops a personalized action plan (10 minutes) Session 2 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan (20 minutes) Session 3 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan, including receiving referrals (20 minutes)
Study NCT05841524 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vector flow imaging measurement
Description: Ultrasound measurement, using high framerate measurement techniques.
Study NCT05267600 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC
Description: Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
Study NCT05267600 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous injection of placebo coformulated with rHuPH20, a permeation enhancer
Study NCT05267600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral Prednisone
Study NCT05267600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Oral Prednisone
Study NCT06472024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Verum Acupuncture
Description: Acupuncture therapy uses filiform needles at a perpendicular angle at acupuncture points to produce a therapeutic effect.
Study NCT06472024 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham Acupuncture therapy uses filiform needles but is only attached with tape to acupuncture points
Study NCT04705233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sputum colour chart
Description: 5-point Sputum Colour Chart plus best standard care
Study NCT06548516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group (conventional scalpel surgery)
Description: The patients in the control group will undergo frenectomy using conventional scalpel surgery.
Study NCT06548516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode laser group
Description: The patients in the laser group will undergo frenectomy using a diode laser.
Study NCT06296355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Warning Label
Description: Message displayed on warning label is: WARNING: Consuming ultra-processed food and drinks can cause weight gain, which increases the risk of obesity and type 2 diabetes.
Study NCT06296355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identity Warning Label
Description: Message displayed on warning label is: WARNING: Ultra-processed food.
Study NCT06296355 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Barcode Label
Description: Barcode is displayed.
Study NCT03999853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKR-017
Description: BKR-017
Study NCT06051214 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: thrombogram
Description: blood sampling every month for 12 months
Study NCT06310694 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: intervention group (Elastane circular dressing on sterile transparent dressing)
Description: A circular dressing made of elastane material was placed on the patients in the intervention group on a sterile transparent dressing to provide additional fixation on the peripheral intravenous catheter.
Study NCT04802109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing level D personal protective equipment
Description: rubber gloves + surgical face mask + general isolation clothing
Study NCT04802109 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: wearing level D personal protective equipment
Description: rubber gloves + surgical face mask + general isolation clothing
Study NCT04802109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing Level C personal protective equipment with N-95
Description: C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing
Study NCT04802109 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: wearing Level C personal protective equipment with N-95
Description: C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing
Study NCT04802109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing Level C personal protective equipment with Powered Air-Purifying Respiratory
Description: C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing+Powered Air-Purifying Respiratory
Study NCT04802109 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: wearing Level C personal protective equipment with Powered Air-Purifying Respiratory
Description: C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing+Powered Air-Purifying Respiratory
Study NCT06569472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targetd CAR-T
Description: Subjects underwent lymphocyte clearance chemotherapy and then received a single intravenous cell infusion
Study NCT06572020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: simulation-based training on blood pressure and ECG measurement
Study NCT06289582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]DPA714 administration IV
Description: brain PET/MRI imaging after \[F-18\]DPA-714 administration
Study NCT04482920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: p-aminohippurate clearance study
Description: To measure kidney blood flow, small doses of a substance called p-aminohippurate (PAH) are used.
Study NCT04482920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Iohexol infusion
Description: To measure glomerular filtration rate (GFR)
Study NCT04730947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg orally once a day
Study NCT04730947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient
Study NCT05074381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leadi
Study NCT05074381 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Needling
Description: During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
Study NCT04658680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG vaccination at first health facility contact
Description: Intradermal injection at first health facility contact: 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine in the left deltoid region.~The strain supplied by the national vaccination programme is provided through UNICEF. Different strains are used interchangeably. The additional BCG vaccines provided through this study will be procured by the Bandim Health Project. Vaccines will be from the WHO list of prequalified vaccines and the same strain will be used in intervention and control health centres.